Alzheimer Disease/Dementia

 
The CMS CED Policy Limits Treatment for Early Alzheimer's Disease: What It Is and How It Works
December 16, 2024

The coverage with evidence development (CED) policy requires enrollment in an active clinical trial for an adult to be eligible for Medicare coverage of treatment for Alzheimer's disease.

Role of Sleep in Dementia and Associated Comorbidities: Daily Dose
December 13, 2024

Your daily dose of the clinical news you may have missed.

Expert Perspectives 2024: Treatment for Agitation in Alzheimer Disease with George Grossberg, MD
December 13, 2024

Agitation affects at least one half of adults with Alzheimer disease; geriatric psychiatrist Grossberg explains the symptoms and new treatments in this year's video series.

Exercise of Any Level Cuts Mortality Risk in People with Dementia: Daily Dose
December 05, 2024

Your daily dose of the clinical news you may have missed.

Pearls for Primary Care: How to Talk About Agitation in Alzheimer Disease with Caregivers
December 04, 2024

A geriatric psychiatrist talks about the importance of asking caregivers about behavior in order to understand and treat agitation in Alzheimer dementia.

New Review Highlights Need to Address Sleep Disturbances in Patients with Dementia
December 02, 2024

Review authors emphasized the need for a more comprehensive approach to dementia management.

For Agitation in Alzheimer Disease, a Novel, Oral NMDA Receptor Antagonist Could be the Next Targeted Treatment
November 27, 2024

Geriatric psychiatrist and neurocognitive researcher George Grossberg, MD, highlights the mechanism of action for the new dextromethorphan/bupropion combination.

Exercise of Any Level Linked to Reduced All-Cause Mortality in Individuals with Dementia
November 19, 2024

Physical activity of any level before and after a diagnosis of dementia was associated with at least a 20% lower risk for all-cause mortality across dementia subtypes.

Agitation in Alzheimer Disease and Antipsychotics Used Off-Label are Not Meant for Each Other
November 18, 2024

Antipsychotic medications are still used to treat potentially harmful acute agitation, George Grossberg, MD, explains, even though the adverse effects are well known.

European Medicines Agency Reverses Opinion on Lecanemab for Alzheimer Disease But Limits Eligible Population
November 15, 2024

The EMA recommendation excludes from treatment adults who are homozygous for the ApoE ε4 gene, a decision that the US Alzheimer's Association does not support, said the president/CEO.